BIOTEST AG VZ O.N./ DE0005227235 /
| 2024-05-15 1:15:18 PM | Chg. +0.100 | Volume | Bid1:15:18 PM | Ask1:15:18 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 27.500EUR | +0.36% | - Turnover: - |
27.500Bid Size: - | 27.900Ask Size: - | 1.63 bill.EUR | 0.10% | - |
GlobeNewswire
1:15 PM
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
1:03 PM
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National ...
GlobeNewswire
1:01 PM
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presente...
GlobeNewswire
1:00 PM
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
GlobeNewswire
1:00 PM
Edible Garden Reports Significant 27.6% Year-Over-Year Revenue Growth for First Quarter of 2024
GlobeNewswire
1:00 PM
Dorman Products expands its catalog of cost-saving and aftermarket-exclusive repair solutions
GlobeNewswire
1:00 PM
Plug to Revolutionize Middle-Mile Delivery with Class 6 Fuel Cell Electric Truck Integration
GlobeNewswire
1:00 PM
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
1:00 PM
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
1:00 PM
Boralex announces a substantial 62% increase in net earnings and continued disciplined development o...
GlobeNewswire
1:00 PM
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
1:00 PM
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the ...
